Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patients, especially elderly males

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Okura, Takafumi ^a   Miyoshi, Ken Ichi ^a   Irita, Jun ^a   Enomoto, Daijiro ^a   Nagao, Tomoaki ^a   Kukida, Masayoshi ^a   Tanino, Akiko ^a   Kudo, Kayo ^a   Pei, Zouwei ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; URIC ACID;

AGED; ARTERIAL WALL THICKNESS; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RISK FACTOR;

AGED; BLOOD PRESSURE; BRAIN; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 84904365730     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05663     Document Type: Article

References (34)

1. Mudd, S. H. et al. Homocysteine and its disulfide derivatives: A suggested consensus terminology. Arterioscler Thromb Vasc Biol. 20, 1704-1706 (2002). (Pubitemid 30470583)
2. Nyfard, O. et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337, 230-236 (1997).
3. Soinio, M. et al. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 140, 94-100 (2004).
4. Cheng, S. W., Ting, A. C. & Wong, J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg. 11, 217-223 (1997). (Pubitemid 27188234)
5. Perry, I. J. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346, 1395-1398 (1995).
6. Towfighi, A., Saver, J. L., Engelhardt, R. & Ovbiagele, B. Factors associated with the steep increase in late-midlife stroke occurrence among US men. J Stroke Cerebrovasc Dis. 17, 165-168 (2008). (Pubitemid 351858611)
7. Selhub, J. et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332, 286-291 (1995).
8. McQuillan, B. M., Beilby, J. P., Nidorf, M., Thompson, P. L. & Hung, J. Hyperhomocysteinemia but not the c677t mutationofmethylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The perth carotid ultrasound disease assessment study (cudas). Circulation. 99, 2383-2388 (1999). (Pubitemid 29218232)
9. Kim, S. J. et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. Stroke. 42, 734-739 (2011).
10. Maron, B. A. & Loscalzo, J. The treatment of hyperhomocystenemia. Annu Rev Med. 60, 39-54 (2009).
11. Loscalzo, J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. J Clin Invest. 119, 3203-3205 (2009).
12. Toole, J. F. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575 (2004). (Pubitemid 38500310)
13. Lonn, E. et al. Heart outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 354, 1567-1577 (2006).
14. Bønaa, K. H. et al. NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 354, 1578-1588 (2006).
15. Cardoso, C. R. et al. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. J Hypertens. 30, 940-947 (2012).
16. Simon, A. et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 20, 159-169 (2002). (Pubitemid 34913777)
17. O'Leary, D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340, 14-22 (1999). (Pubitemid 29024679)
18. Chambless, L. E. et al. Carotid wall thickness is predictive of incident clinical stroke. The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151, 478-487 (2000). (Pubitemid 30471022)
19. Staub, D. et al. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke. 37, 800-805 (2006). (Pubitemid 43731912)
20. Kurata, M., Okura, T., Watanabe, S. & Higaki, J. Association between carotid hemodynamics and asymptomatic white and gray matter lesions in patients with essential hypertension. Hypertens Res. 28, 797-803 (2005). (Pubitemid 47400249)
21. van Dijk, S. C. et al. Homocysteine level is associated with aortic stiffness in elderly: cross-sectional results from the B-PROOF study. J Hypertens. 31, 952-959 (2013).
22. Lim, M. H., Cho, Y. I. & Jeong, S. K. Homocysteine and pulsatility index of cerebral arteries. Stroke 40, 3216-3220 (2009).
23. Jacques, P. F. et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 69, 482-489 (1999). (Pubitemid 29104570)
24. Ricotta, J. J. et al. Up dated society for vascular surgery guidelines for management of extracranial carotid disease. J Vasc Surg. 54, e1-e31 (2011).
25. Matsuo, S. et al. Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53, 982-992 (2009).
26. Manabe, S., Okura, T., Watanabe, S. & Higaki, J. Association between carotid haemodynamics and inflammation in patients with essential hypertension.J Hum Hypertens. 19, 787-791 (2005). (Pubitemid 41486141)
27. Rifkin, M. D. et al. Evaluation of renal transplant rejection by duplex Doppler examination: value of the resistive index. Am J Roentgenol. 148, 759-762 (1987). (Pubitemid 17047767)
28. Okura, T. et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens. 30, 415-422 (2008). (Pubitemid 352009300)
29. Hoffman, M. Hypothesis: hyperhomocysteinemia is an indicator of oxidative stress. Med Hypotheses. 77, 1088-1093 (2011).
30. McCully, K. S. & Ragsdale, B. D. Production of arteriosclerosis by homocysteinemia. Am J Pathol. 61, 1-11 (1970).
31. Marti-Carvajal, A. J. et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 1, CD006612 (2013).
32. Spence, J. D. & Stampfer, M. J. Understanding the complexity of homocysteine lowering with vitamins: The potential role of subgroup analyses. JAMA. 306, 2610-2611 (2011).
33. Spence, J. D. Bvitamin therapy for homocysteine: Renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med. 51, 633-637 (2013).
34. Debreceni, B. & Debreceni, L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther. 30, 227-233 (2012).